Novo Nordisk Struggles to Convince Investors Amid Lilly’s Market Surge

Investors punished Novo stock following Monday's Capital Markets Day, where the drugmaker’s growth targets failed to exceed industry averages. The market remains wary of the looming patent expirations for Wegovy and Ozempic in the early 2030s and the lack of a concrete turnaround plan. Meanwhile, Eli Lilly continues to erode Novo’s position, particularly in the rapidly evolving weight-loss sector.

Lilly CEO Dave Ricks reported that his company’s oral obesity drug, Foundayo, is capturing one-third of new patients in the pill market. Even more critical is Lilly's performance in the Medicare segment; since federal coverage began in July, 700,000 seniors have initiated GLP-1 treatments, with 70% opting for Lilly’s Zepbound. By the second quarter, Lilly commanded a 61% share of the U.S. GLP-1 market, leaving Novo at 39%. While Novo CEO Mike Doustdar remains optimistic that oral formulations will eventually overtake injectables, the company faces the dual challenge of diversifying its portfolio and proving it can reclaim momentum in a space where it was once the undisputed pioneer.